OR WAIT null SECS
Accurately targeted immunotherapies through reliable neoantigen recognition enable personalized medicine development.
Activation and expansion are essential for success in both autologous and allogeneic therapies.
Continuous manufacturing and a quality-by-design development approach are a natural fit.
March 27, 2020
The transgenic mouse R&D platform will support the discovery of fully-human monoclonal antibodies.
March 20, 2020
FDA is offering advice and added flexibility to help sponsors adjust ongoing and planned clinical research programs during the COVID-19 outbreak.
Emergent BioSolutions will help develop and manufacture an oral vaccine candidate and will develop plasma-based antibody therapeutics.
March 19, 2020
Synairgen, a respiratory drug discovery and development company, has announced that it has received expedited approvals to conduct a trial of its inhaled formulation of interferon-beta-1a, SNG001, in COVID-19 patients.
USP technical advisors will offer assistance to drug developers to ensure material quality and testing.
The partners have initiated an observational case-control study of siltuximab in patients with COVID-19 who have developed serious respiratory complications.
March 18, 2020
An NIH study of a COVID-19 vaccine is enrolling Seattle-based healthy adult volunteers.
March 15, 2020
With some FDA inspections on hold, will the US drug supply maintain its quality standards?
March 09, 2020
The company is using its LEAPS peptide technology to develop the immunotherapy, which may be able to reduce COVID-19 viral load and tissue damage.
March 06, 2020
The new center expands the company’s R&D capabilities and will help it advance its portfolio of rare disease gene therapy programs.